Partners

BioTek®

BioTek Instruments, Inc. is a privately held Vermont-based manufacturer notable for microplate instrumentation and bio-analytics software for life science. BioTek designs detection, washing, liquid dispensing and automation products that are compatible with various microplate (microtitre) formats.

They are used by medical and scientific researchers for screening and measurement and numerous other purposes by biotechnology and pharmaceutical companies, university science departments, clinics, food manufacturers and nonprofits. BioTek’s instruments help researchers in the life sciences, drug research, and disease analysis to better understand biological processes at the cellular and molecular level.

Chromogenix

Chromogenix offers hemostasis and fibrinolytic testing solutions based on chromogenic substrates for use in hospitals, clinical laboratories, blood banks and pharmaceutical testing. The Chromogenix product portfolio features over 30 products, including individual chromogenic substrates as well as complete kits with all reagents needed to perform specific analysis on automated instruments. Chromogenix products are manufactured by Instrumentation Laboratory in the US, and distributed and supported by Diapharma Group Inc. in the US and Canada.

The development of the first chromogenic peptide substrate S-2160 in the early Seventies, initiated the introduction of photometry in hematology. Today, Chromogenix has a wide range of chromogenic peptide substrates as well as complete assay kits with applications extending from routine analysis to front line research in both coagulation and fibrinolysis. The tests can be performed manually or on automated analytical systems with high specificity, sensitivity and accuracy. Important, non-chromogenic-based products include kits for APC resistance (an APTT test).

Fianostics

FluoBolt™ technology is based on a physical effect called “Metal Enhanced Fluorescence” which is generated by nanometal structures on the bottom of our micro plates. Those structures create a very strong local electro-magnetic field (“localized surface plasmon”) that greatly enhances the fluorescence of surface bound fluorophores.

The unique features of FluoBolt™ technology enable us to develop direct fluorescence immunoassays with the following benefits:

• High sensitivity
• Single step procedure
• No washing steps
• No enzyme substrates required
• Long term stable signals

Generic Assays

Generic Assays GmbH was established in 2002 by Professor Dr. Dirk Roggenbuck. The company is located in Dahlewitz, south of Berlin.

Generic Assays focuses primarily on products for autoimmune disease research.

Generic Assays is a company that faces the challenges of the market and presents you with a partner who purposefully engaged in the development of new market-relevant products.

Here, innovation and quality are of prime importance, without neglecting cost-effectiveness. These new developments are often carried out in cooperation with academic institutions or routine laboratories e.g. Charité Berlin, Technical University of Dresden or with foreign partners.

For example, the Anti-Ganglioside Dot for the diagnosis of polyneuropathy won a technology transfer prize from the Land Brandenburg in 2005.

For the identification of the main antigen glycoprotein 2 (GP2), for the differential diagnosis of Crohn’s disease, Generic Assays was honored by the IHK Potsdam with the Innovation Award of 2010.

Haematex

Haematex was founded by Thomas Exner PhD, a well known blood coagulation expert specializing in coagulation methods. With decades of experience, he has has made numerous presentations at hematology meetings, published over 100 papers, and has several patents. He is responsible for the one stage dilute Russells Viper venom test (dRVT) that is widely used for detecting lupus anticoagulants. He worked for 20 years in Haematology labs at Royal Prince Alfred and Westmead Hospitals in Sydney, becoming increasingly involved with research, quality control matters and diagnostic test development in the blood coagulation area. His special area of interest includes prothrombotic conditions, detection of which may predict strokes and heart attacks.

Haematex Research patented and developed the XACT test for assessing hypercoagulability. Haematex Research has collaborations with various international diagnostic companies and provides specialized consulting services.

HemaCore

HemaCore was founded in 2010 as a biotech company focused on developing, manufacturing and implementing new technology for hemostasis – thrombodynamics.

Thrombodynamics assay – an innovative coagulation test for risk assessment of blood coagulation disorders – bleedings and thrombosis.

HemaCore helps provide clear and reliable estimation of a subject’s coagulation state, thus giving an ability to prevent thrombotic or bleeding complications.

ImmunoDiagnostics Limited (IMD)

ImmunoDiagnostics Limited (IMD) is a spin-off biotech company from Immunoassay Services (AIS) from the University of Hong Kong (HKU), and has R&D activities in both Toronto, Canada, and Hong Kong. The founders of IMD are academic professoriates with strong research background in immunology, metabolism, cardiovascular medicine, and antibody and protein engineering.  The company has over 12 years of experience in biomarker discovery and development of highly specific immunoassays for both research & in vitro diagnostics (IVD) for major infectious diseases, cardiometabolic disorders and autoimmune diseases.

IMD’s Mission is to be the worldwide pioneer in the production and manufacture of research products regarding immuno-metabolism.

Medipan

MEDIPAN GMBH was founded in 1992 and is an independent, family company.

MEDIPAN started with the marketing of radioimmunoassays for the characterization of thyroid function, disease and tumor markers, with its partners from nuclear medicine laboratories, firstly within Germany. Later, the product portfolio expanded to include non-radioactive tests, and also tests to detect autoantibodies found in patients suffering from autoimmune type 1 diabetes. These diabetes antibody assays are now sold in more than 30 countries, from China to Chile.

MEDIPAN is an innovative and world renowned partner for laboratories and physicians, for the indications above and also in the fields of rheumatic and neurological disease.

QuickZyme

QuickZyme Biosciences has developed a set of assays for the rapid and easy analysis of soluble or insoluble collagens from any tissue and any species.

Collagen assays available from QuickZyme Biosciences:

QuickZyme Soluble Collagen assay
This assay recognizes soluble or (acid/pepsin) solubilized fibrillar collagen. The assay is colorimetric, has a 96-well plate format, and is based on precipitation of collagen with Sirius-Red, an anionic dye with sulphonic acid groups.  The dye is released from the precipitated complex at high pH, followed by colorimetric detection. The assay is optimized such that other proteins (such as albumin) do not interfere. Gelatin (denatured collagen) is not recognized by this assay. The assay requires a soluble or solubilized form of fibrillar collagen.

Application: The assay is used for the measurement of soluble collagen in e.g. cell culture media, and (acid or acid/pepsin) solubilized collagens e.g. from cellular extracts. The assay is not recommended for tissues since most of the tissue collagen is crosslinked and insoluble.

QuickZyme Total Collagen assay
This assay recognizes all types of collagen (mature, immature, procollagen, degraded collagen, crosslinked collagen, collagen from various sources and species). The assay is colorimetric, has a 96-well plate format, and is based on the quantification of hydroxyproline, a modified version of the amino acid proline that occurs almost exclusively in collagen. Hydroxyproline is released from collagen upon acid hydrolysis of the collagen containing sample. Hydrolysis is carried out at 95⁰ C and the hydrolysate can directly be used for hydroxyproline analysis without washing or drying steps.

Application: The assay is used for the quantification of total collagen. This includes all procollagen, unfolded collagen, mature collagen as well as collagen degradation products and gelatin of all collagen types present in the sample. Since the first step is complete hydrolysis of the sample, there are no difficult collagen extraction steps. The assay is applicable for all types of samples including tissue from any species. This assay is influenced by matrix effects due to unidentified substances in tissue samples. Matrix effects can be prevented in many samples through dilution of the hydrolysate. If sufficient dilution of the hydrolysate is not desirable due to low collagen concentration, such as in liver tissue, we recommend the QuickZyme Sensitive Tissue Collagen assay.

QuickZyme Hydroxyproline assay
This assay is similar to the QuickZyme Total Collagen assay, with the difference that protocols and tubes for collagen hydrolysis are not included.

Application: This assay has the same application area as the Total Collagen assay but is intended for customers who have their own method of hydrolysis, or have a collection of hydrolyzed samples to be analyzed.

QuickZyme Sensitive Tissue Collagen assay
This assay is very similar to the QuickZyme Total Collagen assay, but is not influenced by matrix effects, making it the assay of choice for tissues with low collagen concentrations and substantial matrix effects, such as liver tissue.

Application: The assay is used for the measurement of total collagen in (tissue) samples with low concentration of collagen and matrix effects that would require dilution in the QuickZyme Total Collagen assay.

QuickZyme Sensitive Tissue Hydroxyproline assay
This assay is similar to the QuickZyme Sensitive Tissue Collagen assay, with the difference that protocols and tubes for collagen hydrolysis are not included.

Application: This assay has the same application area as the QuickZyme Sensitive Tissue Collagen assay, but is intended for customers who have their own method of acid hydrolysis, or have a collection of hydrolyzed samples to be analyzed.

Rossix

Rossix is a company devoted to thrombosis and hemostasis. The company represents the experience of more than 30 years of development work in the field.

Rossix provides products for use in hemostasis research and quality control and performs contract analyses on a regular basis. The vast majority of Rossix customers are pharmaceutical companies and academic bioscience laboratories.

Mission

The driving force behind Rossix is to support the realization of new pharmaceuticals for improved patient treatment.

By providing methods and reagents, Rossix assists the academic and industrial scientists to set up the appropriate testing methods needed in order to:

• better understand haemostatic disorders.
• design and evaluate drug candidates.
• control and evaluate bio-pharmaceutical production.

Contract Analysis

The core competence of Rossix comprises chromogenic activity and ELISA assays and they have gained a strong competence after performing contract analyses of more than 20 different plasma analytes.

Rossix participates on a regular basis as a reference center in multicenter calibration studies related to primary and secondary WHO standards and our laboratory has a strong track record and the know how to assist you with:

• Exploratory Analysis
• Product Characterization
• Pharmacokinetic studies
• Production Optimization

Method Development

Rossix possesses an in-depth knowledge and experience in development of functional methods within the field of hemostasis.

Rossix has a successful track record of innovative chromogenic assay development, e.g.:

• Factor VIII
• Factor X
• Factor IX
• Factor IXa
• Factor VII
• Factor V
• Factor II
• Protein C

Technoclone

… our quality is your success!

Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH was founded in 1987 by Prof. Dr. Bernd Binder. The main focus of the company was on monoclonal antibodies against components of the coagulation and the fibrinolytic systems. Technoclone was worldwide the first company offering a complete set of ELISAs and of a novel patented system allowing determination of activity and antigen in the same sample (Actibind®) in the field of fibrinolysis.

Acquisition of the former Immuno diagnostics portfolio from the Baxter AG

From 1998 on Technoclone expanded rapidly through the acquisition of the former Immuno diagnostics from Baxter AG and the establishment of an own distribution system in Austria, Germany, the UK and Eastern Europe as well through distributors all over the world.

Production and OEM Products

Today, Technoclone is a world leading producer not only of ELISA systems but also of global and special coagulation tests, control and reference plasmas and protein and lipid diagnostics.

With Ceveron® alpha, a fully automated coagulation analyzer, the portfolio has been completed. Ceveron® alpha is not only a coagulation analyzer for clotting, photometric and immunological, latex based coagulation tests but also offers the unique feature of fluorimetric measurement in the routine as it is demanded for Technothrombin® TGA a new thrombin generation test for the determination of thrombophilic tendency, the research of FVIII inhibitor bypass therapy and anticoagulation research.

Another innovation is the Ceveron® MFU 500, a micro particle filtration unit which can identify micro particles thombogenicity in conjunction with the assay Technothrombin® MP.

Technoclone high quality in vitro diagnostics and test systems are sold worldwide not only under the Technoclone label but are also found as OEM products in the catalogs of international diagnostics companies.

Research and Development

The focus of Technoclone’s research and development is in the field of thrombosis and cardiovascular diseases, the world leading cause of mortality and morbidity. Research and development is pursued in Technoclone’s own research division and in close cooperation with universities and international and national research consortia such as the Fighting Aneurysmal Disease (FAD). Technoclone holds at present more than 10 international patents in the field of diagnosis and therapy of vascular diseases.

Technoclone Brands

• Technoclone
• Technozym®– ELISA (enzyme-linked immunosorbent assay) kits and reagents
• Technothrombin®– thrombin generation assay kits and reagents
• Technochrom®– chromogenic assay kits and reagents
• Technoclot®– clotting assay kits and reagents
• TechnoLEIA®– LEIA (latex enhanced immunoassay) kits and reagents
• Ceveron®– automated coagulation analyzers
• Actibind® – activity and antigen in same sample

Technoclone – Your partner in coagulation

“At Technoclone we see innovation as our duty to help overcome new complexity in the diagnostics of hematological and cardio-vascular disorders. Since 1987, we have been in close collaboration with our global partners from academia, clinical laboratories and industry and on the forefront of diagnostic challenges of tomorrow.” N. B. Binder MD PhD, CSO Technoclone

Teco Medical

The only way to predict the future is to invent it

The Swiss-based TECOmedical Group with subsidiaries in Germany, France and Benelux, is a leading provider of in-vitro specialty test systems in the areas of medical and veterinary diagnostic, biosafety and environmental testing.

In addition TECOmedical develops and evaluate new test systems in collaboration with opinion leaders or as service to pharma, CRO and research organizations.

VLVbio (Peviva)

About Peviva

Peviva is a brand of cell death (apoptosis and/or necrosis) ELISAs and antibodies distributed in the US and Canada by Diapharma. Peviva is now owned by VLVbio.

About VLVbio

VLVbio was established in 2013 in Stockholm Sweden, having been granted exclusive rights to a unique apoptosis marker for keratin 18 (K18) expressing cells of epithelial origin. VLVbio strives to continuously acquire and develop novel intellectual property from the academic research and healthcare market for the detection and quantification of different forms of cell death in normal or pathophysiological circumstances.

VLVbio‘s Corporate Mission

• Invent, develop and market innovative high-quality biomarkers for use in cell-based research in academia, biotech/pharmacy industry and healthcare diagnostics and to expand the product line into related areas of research and diagnostics of different human malignancies.
• Complement these markets through the development of innovative detection and screening technologies.
• Support the advancement of sciences by establishing co-operations with the worldwide community of clinical research as well in partnership with other equally highly committed commercial partner companies.

VLVbio‘s Quality Commitment

VLVbio is committed to providing the highest quality service.

VLVbio’s quality assurance system is certified according to SS-EN ISO 9001 and SS-EN ISO 13485.

The M30 Apoptosense® ELISA, M65®ELISA and M65 EpiDeath® ELISA are registered with the Swedish Medical Products Agency in accordance with the regulations on medical devices and on medical devices for in vitro diagnostics respectively (CE-IVD).

Having produced and delivered thousands of M30 Apoptosense® ELISA and M65® ELISA kits over several years, the quality and reliability of Peviva products have been appreciated and acknowledged by third party publications.

Zacros

With the desire for being a company to “always pursue the cutting edge, now and in the future” they set up the house name “Zacros.” Z for ultimate and Acro (Greek) for extreme. The logo colors green (land) and blue (sky) are a motif of their basic technologies representing multi-layer.

Zacros is ISO 9001:2008 certified for its quality control management system and ISO 14001:2004 certified for its environmental management system in six plants and related departments (including the Head Office, R&D Laboratory, branch and sales offices).

“ZACROS®” is registered as a trade mark for FUJIMORI KOGYO CO., LTD., Tokyo, Japan.